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Immune system-related pathology is common in ataxia-
telangiectasia (A-T) patients and mice that lack the
protein kinase, A-T mutated (ATM). However, it has
not been studied how ATM influences immune re-
sponses to a viral infection. Using the lymphocytic
choriomeningitis virus (LCMV) infection model, we
show that ATM/ mice, despite having fewer naïve
CD8 T cells, effectively clear the virus. However,
aberrant CD8 T-cell responses are observed, includ-
ing defective expansion and contraction, effector-to-
memory differentiation, and a switch in viral-epitope
immunodominance. T-cell receptor-activated, but not
naïve, ATM/ splenic CD8 T cells have increased
ribosomal protein S6 and Akt phosphorylation and
do not proliferate well in response to IL-15, a cytokine
important for memory T-cell development. Accord-
ingly, pharmacological Akt or mammalian target of
rapamycin complex 1 (mTORC1) inhibition during
T-cell receptor activation alone rescues the IL-15 pro-
liferation defect. Finally, rapamycin treatment during
LCMV infection in vivo increases the number of mem-
ory T cells in ATM/ mice. Altogether, these results
show that CD8 T cells lacking ATM have hyperactive
Akt and mTORC1 signaling in response to T-cell re-
ceptor activation, which results in aberrant cytokine
responses and memory T-cell development. We spec-
ulate that similar signaling defects contribute to the
immune system pathology of A-T, and that inhibition
of Akt and/or mTORC1 may be of therapeutic
value. (Am J Pathol 2011, 178:2740–2751; DOI:
10.1016/j.ajpath.2011.02.022)
2740Ataxia-telangiectasia (A-T) is a human disease caused
by mutations in the gene encoding the PI3-kinase-like
protein kinase A-T mutated (ATM).1 A-T is a multifaceted
disease with complex pathology. Cerebellar degenera-
tion underlies the hallmark ataxia symptoms, but another
prominent issue is immune system-related pathology, in-
cluding immunodeficiency and lymphoid cancers.2 A-T
patients commonly acquire hematological malignancies
(eg, leukemia and lymphoma) that together with recurrent
bronchial infections account for most of the mortality from
the disease.3 ATM gene knock-out mouse models of A-T
exhibit many features of the human disease,4–6 including
sexual immaturity, immune system defects, hematopoietic
stem cell defects, and thymic lymphoma, the latter of which
is the most common cause of death in these animals.4,7
Immunodeficiency associated with decreased produc-
tion of immunoglobulins A, E, and G2, and thymic hypo-
plasia has been documented in A-T patients.8,9 The latter
involves decreased peripheral CD4 and CD8 T-lym-
phocyte pools resulting from developmental defects in
the thymic microenvironment.9 Because ATM is recruited
to double-strand breaks, it is likely that defects in the
V(D)J recombination process, which results in a block in
differentiation at the CD4/CD8 double-positive stage
in the thymus, cause lower thymic output of mature CD4
and CD8 cells. This is corroborated by the ability of a
functional T-cell receptor (TCR)- transgene to rescue
the deficit in peripheral T cells in ATM/mice.10 Despite
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tients, the immune function of mature T cells has been
reported to be essentially normal.11 However, to date,
there have been no studies of how deficiency of ATM
affects the response to an infection in A-T patients or in
the mouse models of the disease.
The best-defined role for ATM is in the nuclear DNA
damage response2,12; however, other functions for ATM
have been described.12,13 For example, ATM is important
for mitochondrial homeostasis,14,15 insulin signaling,13,16
phosphorylation of 5’-AMP-activated protein kinase
(AMPK),17–19 and activation of Akt.16,20 In addition, ATM
signals to TSC2 in response to reactive oxygen species,21
to inhibit mammalian target of rapamycin complex 1
(mTORC1) that itself is regulated by AMPK and Akt.22–24
Finally, treatment of mice with the mTORC1 inhibitor rapa-
mycin significantly increases the life span of ATM/ mice
by delaying development of thymic lymphoma.25 Alto-
gether, these results highlight how the loss of ATM might
disrupt the integration of signals that feed into the nutrient-
sensing mTORC1 pathway.
The CD8 T-cell response is a crucial arm of the adap-
tive immune system. In response to an infection, these
cells are activated through the TCR, proliferate, and dif-
ferentiate into cytotoxic effector cells that kill infected
cells. Most of these cells die after clearance of the patho-
gen, but a subpopulation survives, loses effector cell
properties, and become memory T cells.26,27 Memory T
cells are important for fighting recurrent infections, as
they are programmed to respond faster and more effec-
tively to the pathogen. The CD8 T-cell response to in-
fection involves differentiation into short-lived effector
cells and memory-precursor cells26,28 that can be moni-
tored based on surface expression of KLRG1 and CD127
markers. Effector CD8 T cells are preferentially repre-
sented in the KLRG1hi population,29,30 whereas cells that
are CD127hi, which is the receptor for IL-7, and KLRG1lo
preferentially become long-lived memory T cells.31–33
The response of CD8 T cells to TCR activation and
the pathways involved in effector and memory cell differ-
entiation are well-documented.34 These include roles of
the AMPK and mTORC1 pathways at several levels. For
example, TCR activation leads to rapid activation of
AMPK in response to Ca2 signaling, presumably in an-
ticipation of the enormous energy demand required for
T-cell expansion.35 In addition, we have shown that
AMPK/mTORC1 signaling dynamically regulates mito-
chondrial biogenesis during TCR activation.36 Finally,
treatment of mice with the AMPK activator metformin or
the mTORC1 inhibitor rapamycin enhances memory T-
cell differentiation by boosting fatty acid oxidation.33,37
Similarly, mTORC1 regulates differentially effector and
memory T-cell commitment,38 and it is a negative regu-
lator of memory T-cell differentiation in mice.33,37,39
The goal of this study was to determine how loss of
ATM affects normal CD8 T-cell activation and differen-
tiation upon viral infection and to understand how altera-
tions in mTORC1 and related pathways due to lack of
ATM might contribute to the immune-related pathology of
A-T using ATM/ mice as a model of the disease andthe well-characterized murine lymphocytic choriomenin-
gitis virus (LCMV) infection paradigm.
Materials and Methods
Mice and Viral Infections
The wild-type (ATM/) and ATM/ mice (129SvEV
background) were generated by crossing inbred
heterozygous ATM/ mice (obtained from the Howard
Mount, University of Toronto) and were maintained ac-
cording to approved Institutional Animal Care and Use
Committee protocols. Genotyping was performed ac-
cording to the PCR conditions outlined by the Jackson
laboratory (Bar Harbor, ME). For LCMV infection studies,
4-week-old mice were infected with 2  105 Pfu LCMV-
Armstrong (i.p.) as described.40 Viral titers were mea-
sured by a plaque assay as described.41 Rapamycin
treatment in ATM/ and ATM/ animals was performed
by the protocol of Araki et al.33 For CD8 T-cell analyses
from blood, infected mice were bled via retro-orbital
bleeding procedure prescribed by Yale Animal Re-
sources Center, and total blood cells were isolated after
processing the blood by lysing the red blood cells using
0.83% ammonium chloride. Cells were processed and
analyzed by fluorescence-activated cell sorting (FACS).
TCR Activation and Cytokine Culturing of
T Lymphocytes in Vitro
For in vitro experiments, fresh spleens from 10-week-old
mice were taken and total lymphocytes were prepared after
lysing the red blood cells osmotically with 0.83% NH4Cl
buffer for 2 minutes. Cells (1  105) were seeded in indi-
vidual wells of 96-well plates coated with 10 g/mL anti-
CD3 and anti-CD28 antibodies in 1 PBS overnight at 4°C.
When required, CD8 T lymphocytes were purified using
CD8-positive miltenyi magnetic beads according to the
manufacturer’s instructions (Miltenyi Biotec Inc., Auburn,
CA). For IL-2 or IL-15 treatments, 2.5  104 or 1  105
CD8 T lymphocytes that were TCR activated for 72 hours
were cultured in 12-well tissue culture plates coated with 10
pg/mL mouse IL-2 or IL-15 (eBioscience, San Diego, CA).
After 36 hours, 10 ng/mL IL-2 or IL-15 was added to ensure
constant exposure to the cytokines. Where indicated, 10
nmol/L triciribine (Enzo Life Sciences International, Inc.,
Plymouth Meeting, PA) or 10 nmol/L rapamycin (Sigma-
Aldrich, St. Louis, MO) were added during the TCR activa-
tion stage or cytokine stage, or both. During TCR activation,
the drugs were provided twice, first at 24 hours and second
at 48 hours to ensure constant drug action on all cells. The
concentrations used were determined from pilot experi-
ments aimed at finding doses that do not affect proliferation
during TCR in both wild-type and ATM/ CD8 T cells.
Drug vehicle controls were always performed in parallel.
Cells were stained with 0.4% trypan blue and the live cells
were counted microscopically using a hemocytometer.
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For intracellular staining with phospho-S6-alexafluor 433,
tumor necrosis factor-, IL-2 or interferon-, 1  106 CD8
T cells, or total splenocytes were fixed and permeabilized
using the BD Cytofix/Cytoperm kit (BD Biosciences, San
Jose, CA). Surface staining with different markers was per-
formed using appropriate dilutions of antibodies, either as a
cocktail or individually in 1 PBS buffer containing 0.5%
fetal calf serum. Cells were incubated at 4°C or on ice for 20
minutes, washed three times in 1 PBS, and were then
re-suspended in 1 PBS containing 0.1% fetal calf serum.
For assaying cell death by FACS, cells were stained with
propidium iodide according to the instructions using the BD
AnnexinV/PI staining kit and assayed by FACS. The FACS
analysis was performed using either a BD FACS Calibur or
BD LSRII (Yale Cell Sorter Core Facility, New Haven, CT)
and the data were analyzed using FlowJo software (Tree
Star, Inc, Ashland, OR). Median fluorescence intensities
were used for comparative analyses. Prism software was
used to plot graphs and for statistical analyses. Themean
SD was determined from at least three biological replicate
samples and P values, which were determined using un-
paired two-tailed student’s t-test; they are indicated when
appropriate in the figures, with values 0.05 interpreted as
statistically significant.
Immunoblotting
Whole-cell protein extracts were prepared as follows:
CD8 T cells (5  106) were lysed in 40 to 50 L cold
lysis buffer [50 mmol/L Tris–HCl, pH 8.8, 150 mmol/L
NaCl, 0.5% Tween 20, 0.5% Triton-X 100, 0.1% SDS, 2
mmol/L EDTA, 10% glycerol, 1  complete mini, EDTA
free protease inhibitor cocktail (Roche Diagnostics, Indi-
anapolis, IN), 1 phosphatase inhibitor cocktail II (AG
Scientific, San Diego, CA)] at 4°C for 2 hours with careful
pipetting once every 15 to 20 minutes. The resulting cell
lysate was centrifuged at 13,000 rpm for 10 minutes and
the soluble extract was analyzed after the protein con-
centration was determined using a Bio-Rad protein assay
kit (Bio-Rad Laboratories, Hercules, CA).
Protein (20 g) prepared as previously described was
separated on 10%SDS polyacrylamide gels and then trans-
ferred electrophoretically to polyvinylidene difluoride mem-
branes. Membranes were then blocked with 5% bovine
serum albumin/TBST (10 mmol/L Tris–HCl, pH 8.0, 150
mmol/L NaCl, 0.05% Tween 20) for 30 minutes and then
incubated with the desired primary antibody (in 5% bovine
serum albumin/TBST) overnight at 4°C. Blots were rinsed
five times with 1 TBST for 5 minutes and then incubated
with the corresponding secondary antibody (5% bovine
serum albumin/TBST) at 4°C for 1 hour. Blots were then
washed five times for 10 minutes with TBST, and the cross-
reacting proteins were visualized using the Western Light-
ing chemiluminescence reagent plus kit (Perkin-Elmer LAS,
Inc., Waltham,MA) to expose X-ray film. Exposed films were
developed and imaged with Bio-Rad VersaDoc using
Quantity One software (Bio-Rad Laboratories). For serial
Western blots, the membrane was stripped using RestoreTM Western blot stripping buffer (Pierce, Rockford, IL) and
probed again as previously described.
The antibodies used for the Western analysis were as
follows: acetyl-CoA carboxylase or ACC (#3662), pSer79
ACC (#3661), pThr172-AMPK (#2535), AMPK (#2603),
S6 (#2217), pSer235 S6 (#4858S), phosphatase and ten-
sin homolog (PTEN) (#9559), phospho-PTEN (#9554S),
pSer473 Akt (#4060S), pThr308 Akt (#9275S), and Akt
(#9272), all purchased from Cell Signaling (Danvers,
MA). Anti-actin antibody (A5060) from Sigma was used
as a loading control. All primary antibodies were used at
a 1:1000 dilution. Horse-radish peroxidase (HRP)-conju-
gated secondary antibodies, donkey anti-rabbit IgG (sc-
2313), and goat anti-mouse (sc-2314) were purchased
from Santa Cruz Biotechnology (Santa Cruz, CA) and
were used at a 1:10,000 dilution.
Results
ATM/ Mice Have Reduced Antiviral CD8
T-Cell Responses to LCMV Infection
Before taking advantage of the LCMV infection model sys-
tem, we ascertained differences in T cell populations in
uninfected ATM/ and age-matched, wild-type (ATM/),
littermate control mice. The majority of ATM/ mice from
our strain succumb tomalignant thymic lymphomawithin 15
to 20 weeks. At 10 weeks, we found that based on the
distribution of the four populations of thymic T cells (CD4
CD8, double-positive; CD4 CD8, double-negative;
CD4 CD8, CD4 single-positive; CD4 CD8, CD8 sin-
gle-positive) ATM/ mice had fewer total thymocytes than
the control, wild-type animals, a greater percentage of dou-
ble-positive, and a deficit in both single-positive populations
(see Supplemental Figure S1 at http://ajp.amjpathol.org).
Some of the ATM/ mice had a twofold to threefold in-
crease in total thymocytes compared to the control wild-
type mice, nearly all of which were double-positive, indicat-
ing the beginning stages of thymic lymphoma
development.5,25 As previously reported,9 our ATM/
mice also had deficits in total splenocytes, CD8 T lympho-
cytes, and CD4 T lymphocytes (see Supplemental Figure
S1B at http://ajp.amjpathol.org).
To avoid complications from double-positive prolifera-
tion and thymic lymphoma, we infected 4-week-old
ATM/ and age-matched wild-type littermate control
mice with LCMV-Armstrong and monitored their response
weekly for 6 weeks following viral infection. Before infec-
tion the ATM/ mice had fewer splenocytes, CD8 T
cells, and CD4 T cells in the spleen (Figure 1, A–C).
Likewise, CD8 T cells were also depleted in blood, yet
they had normal expression of markers of activated T
cells (see Supplemental Figure S2 at http://ajp.amjpathol.
org). At postinfection day 8, we observed typical expan-
sion of total splenocytes, CD8, and CD4 T cells (Figure
1, A–C), as well as viral-specific CD8 T cells (Figure
1D), coincident with elimination of LCMV (no virus in the
blood at postinfection day 8) in the wild-type mice. This was
followed by a typical contraction of these same cells types
in wild-type mice measured at postinfection day 41 (Figure
re analy
red t-tes
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edly different. First, at day 8, the total number of splenocytes
(Figure 1A), and CD8 and CD4 T cells (Figure 1, B and
C) were substantially reduced compared to the wild-type
mice, no doubt stemming, at least in part, from the T-cell
lymphopenia before infection. Second, both the expansion
(comparing postinfection day 8 with day 0) and contraction
(comparing postinfection day 41 with day 8) of all these cell
types was blunted significantly compared to that in wild-
type mice. In the end, the number of viral-specific CD8 T
cells at postinfection day 41 was twofold to threefold lower
in ATM/ mice (Figure 1D).
Next, we examined the response of viral-specific
CD8 T cells in the blood and found that the overall
frequency of CD8 T cells in the ATM/ mice lagged
behind that in wild-type mice during the first 2 weeks
postinfection, but eventually caught up (Figure 1E). We
also observed a change in the LCMV immunodominance
Figure 1. Fewer splenic T cells and altered immunodominance hierarchy
lymphocytic choriomeningitis virus (LCMV) infection. A: Total splenocytes in
at day 0 (d0), day 8 (d8), and day 41 (d41) post-LCMV infection. B: Total sple
mice. C: Total splenic CD4 T cells at d0, d8, and d41 post-LCMV infection of
d8 and d41 post-LCMV infection in ATM/ and ATM/ mice, respectively.
blood mononuclear cells (PBMCs) in wild-type and ATM/mice at d0, d8, d
and DbGP33-CD8 T cells at d0, d8, day 15, day 20, day 30, and d41 post-
ATM/ mice were analyzed in two separate experiments on d0; the combi
and 5 ATM/ mice analyzed on d8 postinfection and a total of 7 ATM/ an
For blood analyses in data from E and F, 10 ATM/ and 9 ATM/ mice we
indicated directly or by asterisks, which represent P values from an unpaihierarchy in the ATM/ mice. That is, the percentageof the most immunodominant T-cell population, the
DbNP396-404
 LCMV-specific CD8 T cells, was also con-
siderably reduced in the blood of ATM-deficient mice
relative to wild-type during the first 3 weeks after infection
(Figure 1F, left panel). However, the frequency of a more
subdominant T-cell population in wild-type mice, the
DbGP33-41
 LCMV-specific CD8 T cells, were compa-
rable, if not higher, at all time points examined in the
ATM/ mice (Figure 1F, right panel). Thus, the normally
subdominant GP33-41-specific CD8
 T-cell response was
enhanced in the ATM/ mice. Similar relative immu-
nodominance relationships were observed when viral-spe-
cific splenic CD8 T cells were compared (Figure 1D).
Altogether, these results show that ATM is required for
optimal formation of virus-specific effector CD8 T cells
during an acute viral infection and the normal response to
epitopes. Furthermore, our results implicate a combina-
tion of effects are responsible for these T-cell pheno-
 T cells in ataxia-telangiectasia mutated (ATM)/ mice in response to
pe ATM/ (black circles in A–D) and ATM/ (grey squares in A–D) mice
 T cells at d0, d8, and d41 after post-LCMV infection ATM/ and ATM/
and ATM/ mice. D: Total DbNP396-CD8 and DbGP33-CD8 T cells at
l CD8 T cells in the blood (expressed as the number in 1  106 peripheral
y 20, day 30, and d41 post-LCMV infection. F: Percentage of DbNP396-CD8
fection in wild-type and ATM/ mice, respectively. A–C: 5 ATM/ and 5
from two separate experiments is shown representing a total of 5 ATM/
/ mice analyzed on day 41 postinfection from two separate experiments.
zed in two independent experiments. Statistically significant differences are
t of 0.05.in CD8
wild-ty
nic CD8
ATM/
E: Tota
ay 15, da
LCMV in
ned data
d 8 ATMtypes, including a lower number of CD8 T cells preinfec-
ences ar
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response to the viral infection. Despite these demonstrable
defects, ATM/ mice were capable of clearing LCMV ef-
fectively.
Abnormal Memory CD8 T-Cell Development
and Decreased Formation of TCM Cells in the
Absence of ATM
Next, we examined the development of memory CD8 T
cells after LCMV infection and found that the total number of
LCMV-specific memory CD8 and CD4 T cells that formed
was about twofold lower in the absence of ATM (Figure 2A).
Despite this reduction in overall memory T-cell number,
the percentage of total and viral-specific memory CD8 T
Figure 2. Defective memory CD8 T-cell differentiation ataxia-telangiectasia m
DbGP33-CD8 and DbGP61-CD4 memory T cells in spleens from ATM/ an
Comparison of median fluorescence intensities (MFI) obtained from fluorescen
necrosis factor-, and IL-2 of DbGP33-CD8 T cells from ATM/ and ATM/ m
in DbGP33-CD8 T cells from in ATM/ and ATM/ mice at days 8 and 41 p
the results. D: Top row, percent KLRG1hi, CD127hi, and CD62Lhi DbGP33-CD8
line) and ATM/ (dashed gray line) mice. Bottom row, percent KLRG1hi, C
ATM/ (black circles) and ATM/ (grey squares) mice are shown. Whereas fo
and 9 ATM/ mice are shown, and for the spleen, the combined data from se
wild-type and 9 ATM/mice on day 41 are shown. Statistically significant differ
t-test of 0.05.cells in the spleen of ATM/ mice was comparable,albeit moderately reduced, to that in wild-type mice. As
observed in the blood, dominance of the GP33-41-specific
CD8 T-cell response was observed in splenic memory
CD8 T cells in ATM/ animals (see Supplemental Fig-
ure S3 at http://ajp.amjpathol.org).
The memory CD8 T cells that did form in the absence of
ATM were functional, producing similar amounts of interfer-
on-, tumor necrosis factor- and IL-2 as wild-type cells
when reactivated in vitro (Figure 2B). However, the expres-
sion of granzyme B (a potent cytotoxic molecule) was no-
ticeably increased in the ATM-deficient CD8 T cells rela-
tive to the wild-type cells at both days 8 and 41, which
represent effector and memory time points, respectively
(Figure 2C). This suggested that the memory CD8 T cells
were in a more “effector-like” state, as opposed to a resting
TM)/mice post-LCMV infection. A:Number of viral specific DbNP396-CD8,
/ mice at day 41 after lymphocytic choriomeningitis virus (LCMV) infection. B:
ted cell sorting (FACS) analyses of intracellular staining of interferon-, tumor
ay 41 postinfection. C: Relative intracellular expression of granzyme B (GzmB)
tion. The MFI from wild-type cells was given a value of 1.0 for normalization of
at days 8, 15, 20, 30, and 41 in the blood of LCMV-infected ATM/ (bold black
and CD62Lhi DbGP33-CD8 T cells at days 8 and 41 post-LCMV infection for
od, the combined data from two separate experiments representing 7 ATM/
xperiments representing 5 pairs of wild-type and ATM/ mice on day 8 and 7
e indicated directly or by asterisks, which represent P values from an unpairedutated (A
d ATM
ce-activa
ice at d
ostinfec
T cells
D127hi,
r the blo
parate ememory state, which prompted us to more closely compare
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sence of ATM. During LCMV infection in wild-type mice, the
majority of effector cells generated are terminally differenti-
ated cells that do not persist long term after infection.29,32
These end-stage effector cells express high amounts of an
inhibitory receptor KLRG1 and low amounts of the IL-7R
(CD127), which is associated with memory CD8 T cell
survival.42 In contrast, a smaller subset of effector cells de-
velop into “memory precursor cells” that preferentially survive
after infection and can be distinguished by the inverse expres-
sion pattern of KLRG1 and IL-7R (ie, these cells are KLRG1lo
CD127hi).40,43 Thus, as memory CD8 T cells form and ma-
ture, the frequency of KLRG1lo CD127hi cells increases with
time. Moreover, “central” memory (TCM) CD8
 T cells, which
can be distinguished from “effector” memory (TEM) CD8
 T
cells by increased expression of CD62L, also gradually accu-
mulate with time.43 TCM cells home to lymphoid organs and
have higher proliferative (and often protective) capacity on
re-infection relative to CD62Llo TEM CD8
 T cells.43,44
We found that initially the formation of LCMV-specific
terminally differentiated (KLRG1hi CD127lo) and memory
precursor (CD127hi KLRG1lo) effector cells was very similar
between wild-type and ATM/ mice in both the blood and
the spleen (Figure 2D). However, at later time points in the
blood (ie, days 15 through 41 postinfection), the antiviral
CD8 T-cell population in ATM/ mice contained a sub-
stantially larger percentage of KLRG1hi CD8 T cells than
the wild-type animals (Figure 2D, left panel). Consequently,
fewer CD127hi KLRG1lo and CD62Lhi (TCM) memory CD8

T cells accumulated in the ATM/ mice (Figure 2D, right
two panels). On day 41, ATM/ mice also showed accu-
mulation of a larger percentage of KLRG1hi and fewer
CD127hi KLRG1lo and CD62Lhi (TCM) memory CD8
 T cells
in spleen (Figure 2D). Together these data show that ATM-
deficiency impairs the maturation of memory CD8 T cells,
accompanied by a preferential maintenance of GzmB
KLRG1hi CD127lo CD62Llo TEM cells.
ATM/ CD8 T Cells Exhibit a Proliferation
Defect in Response to IL-15
To probe the nature of the effector to memory differenti-
ation phenotype we elucidated in ATM/ mice in vivo,
we activated splenic CD8 T cells in vitro with IL-2, a
potent T-cell mitogen, or IL-15, a cytokine required for
memory T-cell proliferation and maintenance in vivo. This
approach has been shown by others to skew the CD8 T
cells toward TEM- and TCM- as with phenotypes, respec-
tively,45,46 and consists of two primary phases in which
the T cells are first activated via their TCR for 3 days,
followed by 3 days of culture with IL-2 or IL-15 (Figure 3A).
We confirmed this through our own analysis of the effects of
IL-2 and IL-15 under these conditions on the memory cell
markers, CD127, and CD62L (see Supplemental Figure S4
at http://ajp.amjpathol.org). After treatment with IL-15, a sig-
nificant proliferation defect was observed in the ATM/
CD8 T cells, whereas no such defect was observed in cells
treated with IL-2 (Figure 3B). Neither cytokine treatment re-
sulted in significant cell death to confound the experiment
(Figure 3E). Thus, ATM-deficient CD8 T cells are specificallyimpaired in responding and proliferating to IL-15, a critical
cytokine for TCM memory CD8
 T-cell homeostasis.46,47
TCR-Activated ATM/ CD8 T Cells Sustain
Activated Akt Phosphorylation after IL-15, Treatment,
and Inhibition of Akt during TCR Activation Restores
Proliferation in Response to IL-15
One major pathway that is downstream of IL-2 and IL-15,
and affects terminal effector cell and TEM formation in
CD8 T cells in vivo is the nutrient-sensing PI3K/Akt/
mTORC1 pathway.33,37,39,45,48,49 Additionally, under cer-
tain conditions, ATM regulates AMPK, an inhibitor of
mTORC1.17–19 Therefore, we probed the activity of these
pathways by Western blot in ATM/ CD8 T lympho-
cytes treated with IL-15 after TCR activation. Compared
to wild-type CD8 T cells, we observed a significant
increase in Akt phosphorylation (both T308 and S473)
(Figure 3C) in the ATM/ CD8 T cells, and this was
associated with increased inhibitory phosphorylation
(S380/T382/383) of PTEN. Unexpectedly, this hyper-Akt
activity did not correlate with increased phosphorylation
of the mTORC1 substrate S6 (Figure 3C), indicating that
CD8 T cells lacking ATM have elevated Akt, but not
mTORC1 activity. Indeed, ATM-deficient CD8 T cells
had increased AMPK activity as demonstrated by hyper-
phosphorylation of AMPK at T172 and its substrate ACC
S79 (Figure 3C). These results suggest that ATM is nec-
essary to properly integrate signals from Akt and AMPK to
mTORC1. In theT-cell context describedherein, the lossof this
function apparently results in decreased PTEN activity and
increased AMPK activity, the net result of which is hyper-Akt
signaling, without subsequent activation of mTORC1.
Because enhanced Akt activation was observed in IL-15
cultured CD8 T lymphocytes, we tested the hypothesis that
inhibition of Akt would rescue the proliferation defect in re-
sponse to IL-15. When the Akt inhibitor triciribine was added,
either during TCRactivation alone or during both phases (TCR
stimulation and IL-15 treatment), IL-15-driven proliferation in
ATM/ cells was considerably augmented (Figure 3D), de-
spite similar increases in cell death in the triciribine-treated
cultures for both wild-type and ATM/cells (Figure 3E). Pro-
liferation of wild-type cells was also enhanced by triciribine
treatment duringTCRactivation alone (Figure 3D, compare left
and middle bars), but not to the same degree as the ATM/
cells. These results indicate that hyperactivation of Akt in the
ATM/condition (and also in wild-type CD8 T cells to a
significant degree) impairs T-cell proliferation in response to
IL-15, and this is rescued by reducing Akt activity.
Inhibition of mTORC1 Signaling Pathway during
TCR Activation Rescues IL-15 Proliferation
Defect of ATM/ CD8 T Cells
The ability of Akt inhibition during TCR activation alone to res-
cue the IL-15 proliferation defect of ATM/ CD8 T cells
(Figure 3B, compare left and middle bars) suggested that
active Akt signaling before or during TCRactivation could lead
to subsequent effects on IL-15-driven proliferation. To address
2746 D’Souza et al
AJP June 2011, Vol. 178, No. 6this directly, we analyzed PI3K/Akt/mTORC1 and AMPK sig-
naling events before and during TCR activation (Figure 4A).
Western blot analysis of TCR-activated ATM/ cells revealed
that Akt was hyperphosphorylated compared to identically
treated wild-type cells, as in IL-15-treated cells, albeit to a
lesser extent than seen after IL-15 treatment (compare Figures
3Cand 4A). However, before TCRactivation,ATM/CD8 T
cells had either normal or hypophosphorylated Akt, suggest-
ing that Akt was hyperactivated inATM/ cells only after TCR
activation (Figure 4A). The major difference observed in the
TCR-activated ATM/ CD8 T cells was considerable up-
regulation of mTORC1 signaling (as measured by S6 phos-
phorylation) (Figure 4A), a difference that was not observed
prior to TCR activation. Next, we followed the kinetics of S6
phosphorylation (using flow cytometry) as a readout of
mTORC1 signaling during the first 24, 48, and 72 hours after
TCR activation (Figure 4B). ATM/ T cells exhibited a similar
degree of up-regulation S6 phosphorylation as wild-type cells
at 24 and 48 hours, but were deficient in down-regulating
mTORC1 at later points (eg, 72 hours) after TCR activation in
vitro (Figure 4B). Similarly, S6 phosphorylation was increased
Figure 3. T-cell receptor (TCR)-activated ataxia-telangiectasia mutated (AT
proliferation defect in response to IL-15 treatment that is rescued by the Ak
lymphocytes to IL-2 and IL-15, which after TCR activation (using anti-CD3
phenotypes in vitro. B: Number of CD8 T cells after IL-15 (right) or IL-2 (
For culturing in IL-2 and IL-15, the starting CD8 T-cell number was 2.5  10
for the IL-15 experiment, and no difference was observed in the IL-2 e
(S380/T382/383), S6 (S235/236), AMPK (T172), and ACC (S79) and the corres
and ATM/ mice treated with IL-15 according to the scheme in A. Actin was
of mice. D: Total CD8 T cells from ATM/ (open bars) or ATM/ (filled b
10 nmol/L triciribine added at the stage indicated by T (ie, during TCR activat
T-cell death evaluated by propidium iodide (PI)-positive cells after IL-15 tre
added at the stage indicated by T. Analysis of cells from ATM/ (open bars
/ /unpaired t-test for the comparison of ATM to ATM without drug treatment i
untreated within in each group/genotype are as indicated.in ATM/ CD8 T cells at day 8 post-LCMV infection in vivo
(Figure 4C). Based on these data, we then hypothesized that
another reason Akt inhibition during TCR activation is able to
rescue the IL-15 proliferation defect in ATM/ cells (Figure
3D) is via down-regulation of the elevated mTORC1 activity
during TCR activation. This was confirmed by the ability of the
mTORC1 inhibitor rapamycin, like triciribine, to rescue the
IL-15 proliferation defect of ATM/ T cells when added just
duringTCRactivation (Figure4D). This rapamycin regimendid
not result in significant differences in the cell death of two cell
types (Figure 4E).
Rapamycin Treatment during LCMV Infection
Improves Memory CD8 T-Cell Formation in
ATM/ Mice
Based on the fact that rapamycin treatment in vitro im-
proves the ability of activated ATM-deficient CD8 T cells
to respond to IL-15 (Figure 4D), and in vivo increases the
percentage and number of KLRG1lo CD127hi CD62Lhi
CD8 lymphocytes sustain heightened Akt phosphorylation and exhibit a
or triciribine. A: Experimental scheme used to test the response of ATM/
-CD28 antibodies) skews the cell populations toward effector and memory
atment of ATM/ and ATM/ splenocytes, according to the scheme in A.
105, respectively. The P value from a two-tailed unpaired t-test is indicated
nt. C: Western blot analyses of phosphorylated Akt (S473, T308), PTEN
unphosphorylated proteins in splenic CD8 T lymphocytes from wild-type
the loading control. Similar results were obtained 3 times from different sets
e after IL-15 treatment according to the scheme, (A) with () or without ()
e or during both TCR activation and IL-15 treatment). (E) Total percent CD8
according to the scheme (A), with () or without ()10 nmol/L triciribine
M/ (filled bars) mice are shown. D and E: The P value from a two-tailedM)/
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33 we hypothesized that ATM/ mice
might mount a better memory response if mTORC1 was
inhibited during an LCMV infection. To test this hypothe-
sis, we treated ATM/ and wild-type mice with rapamy-
cin starting 1 day before LCMV infection to postinfection
day 8 and followed the kinetics of effector and memory
T-cell formation in the blood at postinfection days 8 to 30.
As previously reported in wild-type mice,33 rapamycin treat-
ment substantially decreased the frequency KLRG1hi termi-
nal effector cells and correspondingly increased the num-
ber of CD127hi KLRG1lo CD8 T cells formed postinfection
(Figure 5A). Likewise, rapamycin treatment augmented the
frequency of CD62Lhi TCM cells at 30 days postinfection
(Figure 5A, right panel). Importantly, similar, albeit more
modest, effects on these phenotypes were observed in
the ATM/ mice treated with rapamycin (Figure 5A; see
also Supplemental Figure S5 at http://ajp.amjpathol.org).
These results show that decreasing mTORC1 activity in
ATM/ mice can partially rescue the altered memory
CD8 T-cell development in ATM/ mice in response to
LCMV infection.
Next, we examined the frequency of memory CD8 T
cells in the blood that formed after rapamycin treatment.
Figure 4. Rapamycin treatment during T-cell receptor (TCR) activation resc
CD8 T lymphocytes. A:Western blot analyses (as described in Figure 3C), ex
and 72 hours after TCR activation (post-TCR) (as described in Figure 3A). B:
phosphorylated ribosomal protein S6 (phospho-S6; S235/236) calculated fro
(at 0 hours), and at 24, 48, and 72 hours of TCR activation in vitro. C: Same
shown. The data from 5 ATM/ and 5 ATM/mice were analyzed. D: Total
according to the scheme (A), with () or without () 10 nmol/L rapamycin ad
and IL-15 treatment). E: Total percent CD8 T-cell death evaluated by propid
() or without () 10 nmol/L rapamycin added at the stage indicated by “R”.
D and E: The P value from a two-tailed unpaired t-test for the comparison of
for comparisons of drug treated to untreated within each group/genotype aAs previously reported,33 rapamycin treatment of wild-type mice increased the frequency of LCMV-specific
memory CD8 T cells that formed 30 days postinfection
(Figure 5B). Interestingly, in the ATM/mice, rapamycin
also significantly boosted the population of GP33-41-spe-
cific CD8 T cells at postinfection day 15, but this effect
was diminished by postinfection day 30 (Figure 5B).
However, no effect of rapamycin treatment was observed
in the NP396-404-specific CD8
 T-cell population (Figure
5B). These results suggest that inhibition of the mTORC1
signaling pathway during early CD8 T-cell activation
can have beneficial effects in terms of the immune re-
sponse to viral infections, but that they are not as long
lasting as those seen in wild-type animals.
Discussion
Previous studies of A-T patients revealed mostly intact
immune responses, although mild differences in T-lym-
phocyte function have been demonstrated in some
cases.11,50 Using ATM/mice as a model of human A-T
immune dysfunction, we confirm that the primary immune
response is indeed effective (Figure 2, B and C), and the
IL-15 proliferation defect in ataxia-telangiectasia mutated (ATM)/ splenic
ATM/ and ATM/ cells were collected before TCR stimulation (pre-TCR)
are the median fluorescence intensities (MFI) from intracellular staining for
plots of ATM/ (white bars) and ATM/ (gray bars) CD8 T cells before
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ide (PI)-positive cells after IL-15 treatment, according to the scheme (A), with
of cells from ATM/ (open bars) and ATM/ (filled bars) mice are shown.
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sponses and memory T-cell development are aberrant in
the ATM/ mice (Figures 1 and 2). These findings are
potentially important from a clinical standpoint, because
persistent effector T-cell function as a consequence of a
viral infection, as our results indicate, can potentially
cause inflammation. This could be relevant to the fact that
A-T patients are predisposed to cancer and diabetes,
both of which are influenced by inflammation.3,51 In fur-
ther support of this premise, persistent inflammation is a
major factor that aggravates DSS-induced colitis in
ATM/ mice.52
A second phenotype we observed in vivo in response
to LCMV infection is a switch in T-cell epitope immu-
nodominance relationships in the ATM/ mice (Figure
1F). Shifts in CD8 T-cell immunodominance during early
stages of LCMV infection are influenced by variability
between epitope abundance and affinity, as well as fre-
quency of precursor T-cell population.53 Although we do
Figure 5. Rapamycin treatment during lymphocytic choriomeningitis virus in
(ATM)/ mice. A: Percent of KLRG1hi, CD127hi, and CD62Lhi DbGP33-CD8
(dashed gray) or without (black line) rapamycin treatment between day 1
and DbNP396 CD8 T lymphocytes were analyzed. Statistically significant
t-test of 0.05. PBMCs, peripheral blood mononuclear cells. X-axes denotenot know how the lack of ATM causes this switch, giventhat the NP396 epitope is the most abundant, it is tempt-
ing to speculate that the defects in signaling downstream
of TCR we have identified in ATM/ CD8 T cells (Figure
4A) may dampen its normally strong TCR signal allowing
the less abundant GP33 epitope to now compete more
effectively. In addition, the reduced total number of viral-
specific CD8 T cells produced in the spleen of ATM/
mice could influence the immunodominance phenotype
observed in blood (Figure 1D–1F). We speculate that
such alterations in epitope response, coupled with the
production of fewer viral-specific memory T cells (Figure
1D), if recapitulated in human A-T patients, could result in
susceptibility to secondary infections.
Moving from our characterization of CD8 T-cell re-
sponses to LCMV infection in the ATM/ mice to in vitro
models of memory cell differentiation allowed us to un-
cover other important defects in ATM/ CD8 T cells.
Specifically, we found that TCR-activated ATM/
splenocytes have a significant proliferation defect in re-
improves memory CD8 T-cell development in ataxia-telangiectasia mutated
in ATM/ and ATM/ mice at days 8, 15, and 30 post-LCMV infection with
8 (indicated by the gray shading). B: Same as in A, except total DbGP33
ces are indicated by asterisks, which represent P values from an unpaired
fter LCMV infection.fection
T cells
to day sponse to IL-15 (Figure 3B), a regimen that has been
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ory T-cell-like properties.45 This was accompanied by
hyperphosphorylation of Akt and the mTORC1 substrate
S6 during TCR activation (Figure 4A), the former of which
persisted after IL-15 treatment (Figure 3C). Based on the
fact that inhibition of Akt and mTORC1 during TCR acti-
vation alone rescues the IL-15 proliferation defect of the
ATM/ cells (Figures 3D and 4D), we propose that sus-
tained activation of mTORC1 activity after TCR activation
is a major defect in these cells. This is corroborated by
the observed increase in phospho-S6 in vivo after LCMV
infection (Figure 4C). Furthermore, granzyme B is acti-
vated by mTORC1 signaling,54 and we observed in-
creased levels of granzyme B in LCMV-infected ATM/
mice (Figure 2C). We interpret these results to mean that
one function of ATM is to integrate signals from PI3K and
AMPK to properly regulate mTORC1 activity under differ-
ent conditions and speculate that this may be relevant to
the immunopathology in A-T. That proper balancing of
PI3K/Akt signaling is needed for memory T-cell survival is
likely to be salient in this regard.55 Also, unstimulated
CD8 T cells from ATM/ mice do not exhibit hyper-Akt
and mTORC1 signaling (Figure 4A), which clearly shows
that this signaling defect is manifest only after TCR acti-
vation. Thus, the CD8 T-cell proliferation and differen-
tiation defects observed are most likely downstream ef-
fects of altered Akt/mTORC1 signaling during TCR
activation. No major changes in AMPK or PTEN were
observed in ATM/ T cells before or after TCR activation
(Figure 4A), but these pathways were perturbed after
IL-15 treatment (Figure 3C). Thus, these are candidate
downstream pathways responding to hyper-Akt/mTORC1
during TCR activation in ATM/ CD8 T cells.
If hyperactivation of mTORC1 signaling is the primary
defect in ATM/ cells, as we concluded from our in vitro
studies, then we reasoned that its inhibition should res-
cue at least some of the T-cell defects we observed in vivo
in response to LCMV infection. Finding that rapamycin
treatment during an LCMV infection significantly in-
creased and sustained higher number of memory CD8
T cells in ATM/ mice (Figure 5) supports this conclu-
sion. These results are consistent with those of Araki et
al,33 who showed that inhibition of mTORC1 during early
stages of LCMV infection substantially improves the
quantity and quality of memory T cells in wild-type
mice,33 but our results demonstrate for the first time that
this may be of therapeutic value for a specific disease
state. However, we acknowledge that the rapamycin-
driven increase in memory cell formation in ATM/ mice
was sustained only as long as rapamycin was being
administered, and this was not maintained at later points
postinfection (Figure 5). Thus a more prolonged drug
regimen may be required to achieve substantial benefit
or other factors/pathways are involved in addition to hy-
per-mTOR signaling.
At this point, we do not know the precise reason for
hyperactivation of mTORC1 during TCR activation of
ATM/ CD8 T cells. Two candidates are AMPK and
PTEN, which are negative regulators of mTORC1 via
TSC2 and Akt, respectively;56–58 however, AMPK and
PTEN steady-state levels and phosphorylation appearnormal in TCR-activated CD8 T cells (Figure 4A). Thus,
in this circumstance, lack of ATM appears to lead to
mTORC1 activation through phosphorylation of Akt,
which is most likely by a PI3-kinase-independent mech-
anism. This contrasts the observation that inhibition of
ATM leads to down-regulation of Akt phosphorylation
during insulin signaling.16,59 Thus, lack of ATM activity
appears to have context-dependent affects on Akt phos-
phorylation and mTORC1 activity. This is supported by
our results from IL-15 treatment of TCR-activated ATM/
cells, which leads to increased inhibitory phosphorylation
of PTEN, whereas AMPK is activated (Figure 3C). In this
case, S6 phosphorylation is unaffected, which suggests
that mTORC1 activity is not responding positively to up-
regulation of Akt activity or negatively to up-regulation of
AMPK activity. Thus, again, ATM is apparently needed to
integrate inputs from multiple pathways that affect
mTORC1. Consistent with this premise, ATM activation by
oxidative stress regulates mTORC1 via TSC2,21 Akt and
mTORC1 are up-regulated in ATM/ thymocytes, and
rapamycin delays lymphoma formation in ATM/ mice.25
In conclusion, in this study we gained greater insights
into the immune system dysfunction in A-T that might aid
in developing therapeutic strategies. Using the well-char-
acterized LCMV-infection mouse model, coupled with
studies of cultured splenic T cells, we found that ATM/
mice have altered CD8 T-cell responses, defective ef-
fector-to-memory differentiation, perturbed hierarchy of
T-cell epitope immunodominance, and hyperactivated
Akt and mTORC1 pathways during TCR activation. The
latter results in an inability of ATM/ CD8 T cells to
proliferate in response to IL-15 in vitro, which can be res-
cued by inhibition of Akt or mTORC1 during TCR stimula-
tion. Finally, some of the memory cell defects are rescued
by rapamycin treatment during LCMV infection in vivo,
which is proof of a principle in amousemodel of the disease
that targeting this pathway may be of therapeutic value for
the immunopathology in A-T patients. Furthermore, if hyper-
activation of Akt and/or mTORC1 results in a common mo-
lecular defect in A-T patent cells, targeting these pathways
might also be of therapeutic value for the additional com-
plex pathology of A-T.
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